← All indications
Genital Neoplasms, Female
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
Subtype terms (5)
More specific conditions that are subtypes of Genital Neoplasms, Female in the MeSH hierarchy.
- Fallopian Tube Neoplasms
380 drugs (151 approved, 229 experimental)
- Ovarian Neoplasms
1163 drugs (312 approved, 851 experimental)
- Uterine Neoplasms
150 drugs (100 approved, 50 experimental)
- Vaginal Neoplasms
59 drugs (36 approved, 23 experimental)
- Vulvar Neoplasms
91 drugs (50 approved, 41 experimental)
Drugs by status
Phase 4 trials (7)
Phase 3 trials (24)
- ferric derisomaltose
- iron
- argatroban
- oxycodone
- doxorubicin
- fiber
- gemcitabine
- paclitaxel
- simethicone
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- olanzapine
- prasterone
- prochlorperazine
- carboplatin
- levobupivacaine
- bupivacaine
- enoxaparin
- ondansetron
- sodium dihydrogen phosphate dihydrate
- disodium hydrogen phosphate dodecahydrate
- oxaliplatin
- aprepitant
- semuloparin
- dexamethasone
Phase 2 trials (42)
- piflufolastat
- anlotinib
- atezolizumab
- darbepoetin alfa
- artemisinin
- olaparib
- epoetin
- fulvestrant
- hydroxychloroquine
- aldesleukin
- 13c-pyruvate
- imiquimod
- nivolumab
- bleomycin
- pembrolizumab
- lenvatinib
- niraparib
- paullinia cupana
- pemetrexed
- rc48-adc
- riluzole
- bevacizumab
- dostarlimab
- vgx-3100
- cabozantinib
- apixaban
- modafinil
- cisplatin
- lucitanib
- nilotinib
- +12 more
Phase 1 trials (32)
- fluorothymidine
- rucaparib
- brodalumab
- autologous tumor infiltrating lymphocytes
- temsirolimus
- durvalumab
- gadobutrol
- gm102
- nintedanib
- igf-methotrexate
- autologous natural killer cells
- lurbinectedin
- monalizumab
- pazopanib
- topotecan
- tremelimumab
- autologous chimeric switch receptor modified t cells
- fludarabine
- sildenafil
- tumour infiltrating lymphocytes
- trebananib
- sodium chloride
- py159
- py314
- cd70 car-t cells
- Sudocetaxel zendusortide
- ab-1015
- recombinant oncolytic herpes simplex virus type 1 (r130)
- dk210
- nk042
- +2 more
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (15)
- Eli Lilly
- Helsinn
- Auron Healthcare GmbH
- Huazhong University of Science and Technology
- Aarhus University
- University of Oslo
- University of Southern Denmark
- University of Adelaide
- Assiut University
- University of Copenhagen
- University of Freiburg
- Pacira Pharmaceuticals
- National Guard Health Affairs
- Universitaetsklinikum Schleswig-Holstein
- King Abdul-Aziz University
Organization Involved with Phase 2 Indications (22)
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Plexxikon
- Pfizer
- Novartis
- Catalysis SL
- PharmaMar
- Harvard University
- Gynecologic Oncology Group
- Hoosier Cancer Research Network
- Indiana University
- Nanjing Medical University
- Austin Health
- Olivia Newton-John Cancer Research Institute
- Tel Aviv University
- University of California, Los Angeles
- AGO Germany
- Essex Pharma
- MedServ. GmbH
- Johnson and Johnson
- Jiangsu Cancer Institute & Hospital
Organization Involved with Phase 1 Indications (18)
- Eisai
- Millennium Pharmaceuticals
- Roche
- Wyeth
- BioMed Valley Discoveries, Inc
- GlaxoSmithKline
- Concerto HealthAI
- Boehringer Ingelheim
- GamaMabs Pharma
- Duke University
- University of Tennessee
- University of Toronto
- William Marsh Rice University
- University of Chicago
- University of Texas, Galveston
- Azaya Therapeutics, Inc
- James B. and Lois R. Archer Charitable Foundation
- Gateway for Cancer Research
Organization Involved with Other Experimental Indications (6)